Compare · CBLL vs TMDX
CBLL vs TMDX
Side-by-side comparison of CeriBell Inc. (CBLL) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 3.5x CBLL ($919.2M).
- CBLL has been more active in the news (17 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- TransMedics Group Inc.
- Price
- $23.37-2.46%
- $90.64-3.25%
- Market cap
- $919.2M
- $3.25B
- 1M return
- -
- +18.72%
- 1Y return
- -
- -21.35%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2019
- News (4w)
- 17
- 5
- Recent ratings
- 8
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CBLL
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
- Chief Technology Officer Woo Raymond sold $47,536 worth of shares (1,979 units at $24.02), decreasing direct ownership by 1% to 194,729 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Blumberg Scott sold $36,534 worth of shares (1,521 units at $24.02), decreasing direct ownership by 1% to 146,600 units (SEC Form 4) (tax liability)
- President and CEO Chao Xingjuan sold $145,753 worth of shares (6,068 units at $24.02), decreasing direct ownership by 0.77% to 781,731 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Blumberg Scott exercised 34,502 shares at a strike of $8.47 and sold $863,555 worth of shares (34,502 units at $25.03) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Financial Officer Blumberg Scott
- President and CEO Chao Xingjuan sold $841,292 worth of shares (33,614 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 787,799 units (SEC Form 4)
- President and CEO Chao Xingjuan exercised 33,096 shares at a strike of $3.31, increasing direct ownership by 4% to 821,413 units (SEC Form 4)
- Director Taylor Joseph Michael sold $306,423 worth of shares (13,095 units at $23.40), decreasing direct ownership by 21% to 48,478 units (SEC Form 4)
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)